- £286.19m
- £270.09m
- £48.70m
Brief: Niox Group H1 2026 Rev £24 Mln; Adj EBITDA £8.30 Mln
UK's Niox H1 revenue falls 5% on lower research sales
Brief: Niox H1 Net Income GBP 5.9 Million
Proposed Tender Offer & Notice of General Meeting
Interim Results
Trading Update
Director/PDMR Shareholding
Brief: Niox Group Announces All AGM Resolutions Passed
Brief: Niox Group Reports Trading For Year In Line With Expectations
AGM Statement
Grant of SAYE options
Director/PDMR Shareholding
Notice of 2026 Annual General Meeting
Exercise of Options, Director Dealing and TVR
Grant of Options
Director/PDMR Shareholding and Total Voting Rights
Holding(s) in Company
UK's Niox 2025 revenue rises 17% on demand for pharma-sponsored clinical trials
Final Results